Forbes contributors publish independent expert analyses and insights. Kim Elsesser covers issues that impact women in the workplace. Organizations regularly use non-disclosure agreements (NDAs) to ...
The FDA accepts the NDA for lorundrostat, a selective aldosterone synthase inhibitor, for adults with uncontrolled or resistant hypertension.
On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance ...
Singh maintained guidance that "we'll see top line results released before the end of this calendar quarter, so by the end of this calendar year" for PALISADE-3. Singh projected that top line results ...
45% of workers surveyed said they'd been subject to a nondisclosure agreement. 39% of workers said they were bound by mandatory arbitration, according to a survey from Penn State. The agreements ...
TOKUSHIMA, Japan--(BUSINESS WIRE)--150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, ...
CHARLOTTE, N.C., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (CHTP) today announced that it has received written guidance from the Director of the Office of New Drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results